Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12257489 | 0.91 | ADORA2B (0.54) | ADORA2BADORA2AADORA3HTR1ACYP2C9 | |
| SCHEMBL8184575 | 0.84 | ADORA2A (0.54) | ADORA2BADORA2AADORA3HTR1ACYP2C9 | |
| SCHEMBL12257433 | 0.82 | ADORA2A (0.45) | ADORA2BADORA2AADORA3HTR1ACYP2C9 | |
| SCHEMBL14893220 | 0.82 | ADORA2A (0.60) | ADORA2BADORA2AMAOB | |
| SCHEMBL12259507 | 0.81 | ADORA2B (0.46) | ADORA2BADORA2AADORA3HTR1ACYP2C9 | |
| SCHEMBL12257272 | 0.81 | ADORA2A (0.44) | ADORA2BADORA2AADORA3HTR1ACYP2C9 | |
| SCHEMBL12257268 | 0.81 | ADORA2A (0.49) | ADORA2BADORA2AADORA3HTR1ACYP2C9 | |
| SCHEMBL12257492 | 0.81 | KDM4E (0.48) | ADORA2BADORA2AADORA3HTR1ACYP2C9 | |
| SCHEMBL12256821 | 0.81 | ADORA2A (0.45) | ADORA2BADORA2AADORA3HTR1ACYP2C9 | |
| SCHEMBL12257432 | 0.80 | ADORA2A (0.43) | ADORA2BADORA2AADORA3HTR1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | LIGAND UK DEVELOPMENT LIMITED (GB) | 2023-03-30 | — | — | US | disclosed |
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | ADORA2B 19/4885ADORA2A 11/4885ADORA3 14/4885 |
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA2B 19/4885ADORA2A 11/4885ADORA3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.